This is the June 2025 edition of the Drugs.com Monthly Update. We cover five significant FDA approvals that are transforming patient care across multiple therapeutic areas.
- Dupixent (dupilumab), newly approved for treating bullous pemphigoid in adults—a painful autoimmune skin disorder primarily affecting patients over 65.
- Mavyret (glecaprevir/pibrentasvir) for acute hepatitis C virus treatment in children as young as 3 years old.
- Yeztugo (lenacapavir), a groundbreaking twice-yearly injectable HIV prevention therapy offering a 99.9% effectiveness rate in clinical trials.
- Enflonsia (clesrovimab-cfor), a new RSV prevention option for neonates and infants that provides season-long protection with a single injection.
- Ibtrozi (taletrectinib), an oral targeted therapy approved for ROS1-positive non-small cell lung cancer in patients with locally advanced or metastatic disease.
Chapters:
- (00:00) - Intro
- (00:24) - Overview
- (00:45) - Dupixent
- (01:38) - Mavyret
- (02:14) - Yeztugo
- (03:14) - Enflonsia
- (03:54) - Ibtrozi
- (04:26) - Outro
Follow Drugs.com:
